Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from IGM Biosciences

Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022

Analyst Ratings for IGM Biosciences

Analyst Ratings for IGM Biosciences

IGM Biosciences (NASDAQ:IGMS) has observed the following analyst ratings within the last quarter:

Why Did Truist Lower IGM Biosciences' Price Target?

Why Did Truist Lower IGM Biosciences' Price Target?

Truist has lowered the price target on IGM Biosciences Inc (NASDAQ:IGMS) to $74 from $80. The analyst Asthika Goonewardene says that the lower price target reflects the Company's Q4 results, deal financials, and increased cost to IGM Biosciences in its Sanofi SA (NASDAQ:SNY) collaboration deal. Related: IGM Biosciences Shares Surge After Oncology / Immunology Pact With Sanofi.…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

10 Biggest Price Target Changes For Wednesday

Morgan Stanley raised the price target on IGM Biosciences, Inc. (NASDAQ: IGMS) from $25 to $30. IGM Biosciences shares fell 4% to $28.32 in pre-market trading.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Mid-Day Market Update: Crude Oil Down 2.5%; IGM Biosciences Shares Jump

U.S. stocks traded higher midway through trading, with the Dow jumping over 250 points on Tuesday.

Mid-Morning Market Update: Markets Open Higher; McCormick Profit Beats Estimates

U.S. stocks opened on a strong note on Tuesday, with the Dow jumping around 350 points this morning.

inkl

Read news from The Economist, FT, and more,
with one subscription

Recap: IGM Biosciences Q4 Earnings

Recap: IGM Biosciences Q4 Earnings

IGM Biosciences (NASDAQ:IGMS) reported its Q4 earnings results on Tuesday, March 29, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

1

Organisations

LyondellBasell Industries

Cooper Companies

Host Hotels Resorts

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play